A trial looking at ofatumumab for mantle cell lymphoma

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Blood cancers
Low grade lymphoma
Lymphoma
Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 2

This trial looked at ofatumumab for mantle cell lymphoma that had come back after treatment.

Mantle cell lymphoma is a rare type of non Hodgkin lymphoma (NHL). Doctors often treat mantle cell lymphoma with chemotherapy, radiotherapy and biological therapy. But it can be difficult to treat, or can come back after treatment.

Ofatumumab (Arzerra) is a type of biological therapy called a monoclonal antibody. Monoclonal antibodies can seek out cancer cells by looking for particular proteins.

Ofatumumab has been used to treat other types of cancer, and doctors hoped it would be useful for treating mantle cell lymphoma.

The aim of this trial was to see how well ofatumumab works for mantle cell lymphoma.

Summary of results

The trial team found that ofatumumab was not likely to be a useful treatment for mantle cell lymphoma.

To begin with, this trial recruited 12 people with mantle cell lymphoma that had come back after treatment. They all had ofatumumab through a drip into a vein, once a week for up to 5 weeks.

When the research team looked at how well the treatment had worked, they found that the lymphoma had

  • Got smaller in 1 person
  • Stayed the same in 6 people
  • Continued to grow in 5 people

The research team had hoped to recruit 34 people for this trial. But when they looked at the results of these first 12 people, they decided not to carry on recruiting.

The most common side effect was extreme tiredness (fatigue) for a couple of days after each dose of treatment. This affected 9 out of the 12 people (75%) in the trial.

The research team concluded that the dose of ofatumumab they used in this trial was not a useful treatment for mantle cell lymphoma.

We have based this summary on information from the team who ran the trial. The information they sent us has been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Simon Rule

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer
University Hospitals Plymouth NHS Trust
Plymouth Lymphoma Trials Unit

Other information

This is Cancer Research UK trial number CRUKE/10/054.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 6967

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Cara took part in a clinical trial

A picture of Cara

"I am glad that taking part in a trial might help others on their own cancer journey.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think